Lexington Medical Secures Growth Investment from Ampersand Capital Partners

Ampersand

Bedford, Massachusetts, April 17, 2025 /PRNewswire/ – Lexington Medical (“Lexington”), a leader in minimally-invasive surgical stapling solutions, today announced a strategic investment by Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in growth equity investments in the healthcare and life sciences sectors. The partnership underscores Ampersand’s confidence in Lexington’s potential to redefine surgical stapling standards and positions the company for accelerated growth in product innovation, smart manufacturing, and global market expansion.

Founded in 2013 and headquartered in Bedford, MA, Lexington Medical designs and manufactures high-performance endoscopic stapling devices, which are proudly made in the USA and used in a wide range of surgical procedures. With international offices in Switzerland, Australia, Germany, and the UK, and a team of approximately 150 employees, Lexington has built a patented portfolio of over 40 SKUs that are trusted by surgeons in more than 35 countries. Its flagship AEON™ and AEON™ Powered Stapling platforms are recognized as the most advanced stapling platforms available, featuring proprietary technologies that deliver superior clinical outcomes.

“The investment from Ampersand is a testament to Lexington’s impressive growth and strategic vision,” said Leon Amariglio, Founder and CEO of Lexington Medical. “This investment will expedite our innovation pipeline, expand our global reach, and create new opportunities for talented professionals to join us in shaping the future of surgical care, all while maintaining our commitment to best-in-class quality control and US manufacturing.”

“Lexington is an impressive company with a strong culture of innovation, exceptional leadership, and a commitment to quality and performance that is unmatched” said Trevor Wahlbrink, General Partner at Ampersand. “We are excited to partner with Leon and his team to further strengthen their position in surgical stapling.”

This partnership comes at a pivotal time as Lexington Medical expands its world-class team to meet the growing demand for its stapling solutions. Interested candidates and collaborators are invited to visit www.lexington-med.com/careers or contact careers@lexington-med.com to learn more about career and partnership opportunities.

About Lexington Medical

Founded in 2013, Lexington Medical, Inc. is a rapidly growing Bedford, Massachusetts-based company disrupting minimally invasive surgical stapling. Its AEON™ Endostapler sets the standard for precision, performance and clinical outcomes, trusted by surgeons in over 35 countries. Rooted in an engineering driven and talent-dense, collaborative culture, Lexington drives continuous innovation through U.S.-based design and manufacturing, working closely with leading surgeons to enhance patient outcomes. Learn more at www.lexington-med.com or follow us on LinkedIn.

About Ampersand Capital Partners

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit AmpersandCapital.com or follow us on LinkedIn.

Categories: News

Tags:

Grupo GSH’S next stage of growth backed by leading global investor CVC

CVC Capital Partners

Grupo GSH (“GSH”), a leading healthcare services provider in Brazil, is pleased to welcome CVC Capital Partners IX as its new majority shareholder. The new partnership will continue GSH’s strong service level culture and accelerate growth in both its existing core markets and through expansion into new product categories and patient services. CVC Funds will acquire the business from Rede D’Or, the largest integrated health care network in Brazil, and from private equity fund Opus Investimentos, which have supported the development of GSH for more than eight years. GSH will remain as the main provider of hemotherapy services to Rede D’Or.

Headquartered in Rio de Janeiro, Brazil, GSH is a pioneer in Brazil’s hemotherapy and nuclear medicine space with leading market positions, delivering mission-critical services and products at an attractive value proposition to hospitals and diagnostic centres. The hemotherapy division serves 31,000 beds in +270 hospitals through long-term contracts providing blood collection, storage and transfusion services. The nuclear medicine division develops and services radiopharmaceutical products and solutions focused on diagnostics and therapeutics for hospitals, diagnostics and cancer centres in Brazil. Facilities include cold kit plant, radiopharmacies and cyclotrons.

Paulo Moll, CEO at Rede D’Or, said: “GSH has demonstrated RDSL’s ability to successfully develop complementary services that enhance our core hospital services, providing the very best care consistent with RDSL’s network. After eight years supporting and nurturing GSH it is time for the business to welcome a new investor to help accelerate its growth and we are delighted to welcome CVC as the new steward for the company. We look forward to working with them and to continuing to offer GSH’s high-quality services to our patients.”

Marcos Faccioli, GSH management representative, commented: “The interest of CVC in GSH confirms the success of our trajectory. A history built with the support of RDSL and Opus together with our employees, clients, suppliers and partners. We are very excited in welcoming CVC as the new majority shareholder and to work with the CVC team on the development of our business and on continuing to provide world class products and services to our clients and their patients.”

Quotes

GSH represents CVC’s first healthcare investment in Latin America, building on our strong local presence in Brazil and our broad healthcare portfolio of over 25 businesses worldwide.

Fernando PintoPartner and Head of Latin America at CVC

Fernando Pinto, Partner and Head of Latin America at CVC, added: “GSH represents CVC’s first healthcare investment in Latin America, building on our strong local presence in Brazil and our broad healthcare portfolio of over 25 businesses worldwide. We are excited to partner with GSH’s management team to continue strengthening its high-quality hemotherapy and fast-growing nuclear medicine services, while also expanding into new complementary areas. We are proud to have been selected as GSH’s next long-term partner.”

The closing of the transaction is subject to approval by the relevant regulatory authorities and is expected in Q3 2025.

Categories: News

Tags:

EQT to sell Karo Healthcare, a Leading Pan-European Consumer health Platform, to KKR

eqt

Karo Healthcare

  • Under EQT’s ownership, Karo has transformed from a Nordic specialty pharma business into a pan-European consumer healthcare platform, driven by strong organic growth, eight strategic acquisitions, and investment in digitalisation and in-house commercial capabilities
  • KKR will support Karo’s continued growth by leveraging its deep sector expertise, global network, and a long-term investment approach to drive innovation, internationalization, and further brand growth and acquisitions
  • Karo now operates a diversified portfolio of trusted consumer health brands with leadership positions in European markets and a scalable, digitally enabled platform

EQT and KKR today announced that EQT VIII fund (“EQT”) has agreed to sell Karo Healthcare (“Karo” or the “Company”) to KKR. The acquisition marks the next chapter for Karo, as it continues to accelerate its growth strategy under KKR’s ownership, building on its transformation into one of Europe’s leading consumer health platforms since EQT’s initial investment.

Karo is a leading pan-European consumer healthcare company headquartered in Stockholm, Sweden. The Company operates an attractive product portfolio spanning core categories such as Skin Health, Foot Health, and Intimate Health, as well as Digestive Health and Vitamins, Minerals & Supplements. During the past five years, Karo has scaled substantially, quadrupling in sales, building leading digital capabilities and establishing market presence to reach consumers in more than 90 countries with top brand positions across European markets.

Under EQT’s ownership since 2019, Karo has undergone a significant strategic repositioning, shifting from a specialty pharmaceutical company focused on the Nordics into becoming a pan-European pure-play consumer healthcare platform. During this time, with M&A having been a cornerstone of Karo’s growth strategy, Karo completed eight acquisitions from industry players which have enriched Karo’s portfolio, strengthened its presence in key markets, and accelerated its entry into new geographies.

Commenting on the transaction, Christoffer Lorenzen, CEO of Karo Healthcare, said: “We’re incredibly proud of what we’ve achieved in recent years and grateful to EQT for their partnership, which has been instrumental in helping us grow and evolve into the business we are today. With KKR as our new owner, we are entering an exciting next phase in our journey. Their global reach, deep sector understanding, and long-term approach make them the ideal strategic partner as we continue to invest in our brands, expand into new markets and meet the evolving health needs of consumers.”

“Karo is a textbook example of EQT’s approach – scaling a local company into a fast-growing sector champion with international reach,” said Erika Henriksson, Partner in the EQT Private Equity advisory team. “Thanks to its consumer centricity, strong M&A track record, and proven brand growth playbooks, Karo is now primed to further expand on its leadership position. We’re proud of what Christoffer and the team have achieved and excited to hand over to a new owner for the next phase.”

Inaki Cobo, Partner at KKR, said: “Karo is a unique platform with high-quality brands, strong digital and commercial capabilities, and a proven strong leadership team. We are thrilled to invest in this European champion’s next phase of growth, drawing on our deep experience in the consumer health space to support continued expansion, innovation, and organic and inorganic growth.” Hans Arstad, Managing Director at KKR, added: “Karo operates in a resilient, growing sector supported by long-term demographic trends and increasing consumer focus on wellness and self-care. We engaged the full capabilities of our firm to deliver this transaction during a period of market disruption and we look forward to supporting Karo’s growth as a value-enhancing strategic partner.”

The transaction is subject to customary regulatory conditions and approvals and is expected to close in the coming months. EQT was advised by Jefferies, Morgan Stanley, PwC and White & Case. Citigroup acted as financial advisor to KKR.

Media Contacts
EQT Press Office, press@eqtpartners.com
KKR, Alastair Elwen, alastair.elwen@fgsglobal.com

About Karo Healthcare
Karo Healthcare is a leading European consumer healthcare company with the purpose of delivering “Smart choices for everyday healthcare”, empowering people to live life to the fullest. Our products are available in more than 90 countries and include trusted original brands such as Lamisil®, E45®, Pevaryl®, Proct®, AlphaFoods, Nutravita, Flux®, Locobase®, Multi-Gyn® and Paracet®. Headquartered in Stockholm, Karo employs about 470 people who work out of Karo’s 13 international hubs. More info: karohealthcare.com.

About EQT
EQT is a purpose-driven global investment organization with EUR 269 billion in total assets under management (EUR 136 billion in fee-generating assets under management), within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on LinkedInXYouTube and Instagram
 

About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Categories: News

Tags:

HealthEdge Secures Strategic Investment from Bain Capital

No Comments
BainCapital

BURLINGTON, Mass. – April 8, 2025 – HealthEdge, a leader in healthcare technology solutions, today announced that it has entered into a definitive agreement to be acquired by Bain Capital. The investment is being made by Bain Capital’s Private Equity team. Financial terms of the private purchase from funds managed by Blackstone were not disclosed.

Founded in 2005, and headquartered in Burlington, Massachusetts, HealthEdge is a next-generation SaaS platform that connects health plans, providers, and patients with a suite of end-to-end digital solutions to automate operations, reduce administrative costs and improve overall health outcomes. HealthEdge currently serves over 115 health plans representing more than 110 million covered member lives across the U.S. Its best-in-class solutions and administrative processing systems have earned the Company repeated recognition from leading market analysts.

“We are pleased to welcome Bain Capital as our new partner as we embark on our next chapter of growth and innovation,” said Steve Krupa, CEO of HealthEdge. “We believe we are well-positioned to achieve our vision of being the long-term partner of choice for health plans as we continue to create deeper integrations between our solutions, which support health plans through claims processing, care management, and member engagement. We are thankful for Blackstone’s support over the last five years and look forward to working with Bain Capital as we remain committed to implementing solutions that will redefine the future of healthcare.”

“HealthEdge is enabling health plans to transition towards a modern tech ecosystem via its cloud-based claims adjudication software and complementary suite of value-added solutions. In a world of growing operational complexity, we believe that HealthEdge can streamline operations, improve care delivery, and increase engagement among healthcare payers, provider, and patients,” said Devin O’Reilly and Paul Moskowitz, Partners at Bain Capital. “The HealthEdge Solutions Suite is a mission-critical system that sits at the heart of the health plan tech stack in one of the most complex HCIT ecosystems we’ve seen. We believe HealthEdge can be a driving force for GenAI enablement at health plans, and we look forward to partnering with the management in the next phase of growth.”

“We are proud to have been part of HealthEdge’s journey over the last five years, partnering with management to evolve the business from an emerging modern software solution for payors to a mission-critical platform of high-value technologies for payors, caregivers, and patients,” said Ram M. Jagannath and Anushka M. Sunder, Senior Managing Directors at Blackstone. “Over the course of our investment, Blackstone partnered with HealthEdge to innovate new solutions, acquire and integrate strategically important software solutions, drive sustained growth, and build a comprehensive technology platform to address challenges across the American healthcare ecosystem. It has been a pleasure driving this phase of the transformation, and we wish Steve, the entire management team, and Bain Capital continued success in driving HealthEdge’s next chapter of strategic growth.”

The transaction is expected to close during the second quarter of 2025, subject to customary closing conditions.

TripleTree is acting as lead financial advisor, Kirkland & Ellis as legal counsel, and Ares Management as lead financing partner to Bain Capital. Evercore and UBS Investment Bank are acting as financial advisors, and Simpson Thacher & Bartlett as legal counsel to Blackstone.
###

About HealthEdge
HealthEdge® is building a future without limits for health plans, where they can deliver better service and care, make more informed decisions and streamline operations. Through an integrated platform of solutions for core administration (HealthRules® Payer), payment accuracy (HealthEdge Source™), provider network management (HealthEdge Provider Data Management), care management (GuidingCare®) and member experience (Wellframe™), health plans can converge their data and harness
automation to drive more informed decisions, improve touchless transaction processing and payment accuracy, foster meaningful collaboration and enhance service and care delivery. HealthEdge is trusted by over 115 health plans covering more than 110 million member lives across the U.S. See what it means to converge without limits at HealthEdge.com and follow us on LinkedIn.

About Bain Capital  
Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management. To learn more, visit www.baincapital.com. Follow @BainCapital on LinkedIn and X (Twitter).

About Blackstone
Blackstone is the world’s largest alternative asset manager. We seek to deliver compelling returns for institutional and individual investors by strengthening the companies in which we invest. Our more than $1.1 trillion in assets under management include global investment strategies focused on real estate, private equity, infrastructure, life sciences, growth equity, credit, real assets, secondaries, and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.

 

 Scott Lessne

Categories: News

Tags:

Office Ally Embarks on Next Phase of Growth and Innovation with New Mountain Capital and Francisco Partners

Franciso Partners

VANCOUVER, WA, NEW YORK & SAN FRANCISCO – April 7, 2025 — Office Ally (or “the Company”), a leading healthcare technology company providing a comprehensive suite of cloud-based clearinghouse and software solutions to a national network of healthcare providers, partners, and health plans, announced a strategic growth investment from New Mountain Capital, a leading growth-oriented investment firm with more than $55 billion in assets under management. As part of the transaction, Francisco Partners, which originally invested in Office Ally in 2021, will also reinvest alongside management.

This investment empowers Office Ally to accelerate its strong growth and product roadmap to become a preeminent next-generation clearinghouse and software provider. With expanded resources, Office Ally will drive greater efficiency, automation, and interoperability across the healthcare ecosystem. Trusted by more than 80,000 healthcare organizations, Office Ally enables the exchange of more than 950 million transactions annually between providers and payers to coordinate patient care and enable healthcare payments.

“We are thrilled to have the opportunity to work with both New Mountain Capital and Francisco Partners on this next chapter of growth for Office Ally,” said Chris Hart, CEO of Office Ally. “The team at Francisco Partners have been incredible enablers of our success over the past several years and the New Mountain Capital team’s investing acumen, strategic insights and operational knowledge across the healthcare technology space make them an ideal partner for us moving forward. On behalf of the entire Office Ally team, we are proud to support the critical work of healthcare providers and payers across the country—and we cannot wait to work with both of these great firms to further our mission.”

Matt Holt, Managing Director and President, Private Equity at New Mountain Capital said, “We are excited to partner with Chris Hart, Francisco Partners and the entire Office Ally team to build a next-generation healthcare technology platform company. We have tracked Office Ally’s innovation record over the past few years and believe that the company is exceptionally well-positioned to lead the modernization effort of payment in the U.S. healthcare systems. Office Ally can leverage its technology and data assets to enable what we see as a modern, real-time payment system, bringing together clinical and administrative processes into a model that’s aligned with an overall shift to outcomes-based payment models. At New Mountain, we have been investing in the modernization of the healthcare system and we plan to bring our ecosystem and network to the benefit of Office Ally. We are excited to support the company’s leadership position in helping to shift the U.S. healthcare systems from a broken system of antiquated processes to a modern, proactive and efficient system that’s better aligned with the health of patients.”

Justin Chen, Partner at Francisco Partners said, “It has been a pleasure and a privilege to partner with Chris and the Office Ally team to accelerate growth and expand the business over the past several years. The team has built an exceptional company with a unique culture, customer-first approach, innovative product roadmap and compelling product suite. We are excited to continue supporting Office Ally’s mission and next stage of growth with our new partners at New Mountain Capital.”

William Blair served as financial advisor and Kirkland & Ellis served as legal advisor to Office Ally and Francisco Partners. Houlihan Lokey served as financial advisor and Ropes & Gray LLP served as legal advisor to New Mountain Capital.

Financial terms of the transaction were not disclosed.

About Office Ally

Office Ally is a healthcare technology company that offers cloud-based solutions tailored for healthcare providers, partners, and payers. Our comprehensive platform is trusted by more than 80,000 healthcare organizations of all sizes from start-ups to the Fortune 100. The Company’s all-payer clearinghouse connects healthcare organizations to a nationwide network enabling the secure exchange of clinical and financial information. For more information visit: www.officeally.com.

About New Mountain Capital

New Mountain Capital is a New York-based investment firm that emphasizes business building and growth, rather than excessive risk, as it pursues long-term capital appreciation. The firm currently manages private equity, strategic equity, credit, and net lease real estate funds with nearly $55 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information, visit: www.newmountaincapital.com.

About Francisco Partners

Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch over 25 years ago, Francisco Partners has invested in more than 450 technology companies, making it one of the most active and longstanding investors in the technology industry. With more than $50 billion in capital raised, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit www.franciscopartners.com.

Under no circumstances does the information contained herein constitute an offer to sell or a solicitation of an offer to buy any security or interest in an investment vehicle managed by New Mountain Capital or Francisco Partners. Any such offer or solicitation can only be made through a definitive private placement memorandum describing the terms and risks of an investment to sophisticated persons who meet certain qualifications under the federal securities laws and are capable of evaluating the merits and risks of the investment. Nothing presented herein is intended to constitute investment advice, and no investment decision should be made based on any information provided herein. It should not be assumed that an investment will be profitable or that the performance of any particular investment will equal its past performance. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in securities, including the potential loss of principal. Past performance is not indicative of future results.

Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs

BainCapital

  • inancing led by new investor Bain Capital with participation from new investor Wellington Management and all existing investors
  • Proceeds to support advancement of ATSN-201 through potential approval and launch as well as preclinical programs to treat inherited retinal diseases
  • Norbert Riedel, PhD, will join Atsena’s Board of Directors

DURHAM, NC, April 2, 2025 – Atsena Therapeutics (“Atsena” or “the Company”), a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the successful close of an oversubscribed $150 million Series C financing. The financing was led by Bain Capital’s Life Sciences team, with participation from an additional new investor, Wellington Management. All the Company’s existing investors also participated in the round, including Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, and the Manning Family Foundation.

Proceeds from the financing will be used to advance Atsena’s lead program, ATSN-201, for the treatment of X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to blindness later in life. The proceeds will also support Atsena’s preclinical pipeline of first-in-class therapies and expand the use of Atsena’s novel spreading AAV.SPR capsid.

“Closing our Series C marks a pivotal moment for Atsena as we advance our transformative ocular gene therapies and fuel our next phase of growth, innovation, and clinical progress,” said Patrick Ritschel, Chief Executive Officer of Atsena Therapeutics. “It follows a productive 12 months of key achievements including securing a partner to advance ATSN-101 to a global pivotal trial for Leber Congenital Amaurosis type 1 (LCA1) and initiating Part B of the ATSN-201 LIGHTHOUSE study for XLRS. We’re grateful for the support of our investors and partners who share our vision for the future of leveraging genetic medicine to reverse or prevent blindness.”

To date, Atsena’s clinical portfolio has received multiple designations by the U.S. Food and Drug Administration (FDA). ATSN-101, for the treatment of LCA1, has received Rare Pediatric Disease designation, Orphan Drug Designation, and Regenerative Medicine Advanced Therapy designation. ATSN-201 has been granted Fast Track, Rare Pediatric Disease, and Orphan Drug Designations. Updated data from the ongoing LIGHTHOUSE Phase I/II clinical trial evaluating ATSN-201 is anticipated later this year.

“We believe Atsena has a unique opportunity to deliver meaningful impact for patients with inherited retinal diseases on the basis of novel science and impressive clinical data generated to date,” said Amir Zamani, a Partner at Bain Capital Life Sciences. “We look forward to supporting Patrick and his strong team as they look to unlock the next phase of Atsena’s growth and innovation while thoughtfully advancing potentially groundbreaking therapies toward patients in need.”

In conjunction with the financing, Norbert Riedel, PhD, a seasoned scientist and biopharmaceutical executive, will join Atsena’s Board of Directors.

Wedbush & Co. served as exclusive placement agent to Atsena for the Series C financing, Cooley LLP acted as its legal advisor.

About Atsena Therapeutics
Atsena Therapeutics (“Atsena”) is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases. The company’s lead program is evaluating ATSN-201 in an ongoing Phase I/II clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to blindness later in life. ATSN-101, Atsena’s first-in-class, investigational gene therapy for Leber congenital amaurosis type 1 (LCA1) has completed a Phase 1 / 2 trial with positive results (https://doi.org/10.1016/s0140-6736(24)01447-8). Atsena is advancing ATSN-101 toward the initiation of a global pivotal trial as part of its exclusive strategic collaboration with Nippon Shinyaku Co., Ltd. Atsena’s pipeline is powered by novel adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal diseases. Founded by pioneers in ocular gene therapy, Atsena is led by an experienced team dedicated to addressing the needs of patients with vision loss. For more information, please visit https://atsenatx.com/.

 

 Scott Lessne

Categories: News

Tags:

Mehiläinen agrees the acquisitions of Regina Maria and MediGroup and welcomes Hellman & Friedman as a new shareholder alongside CVC

CVC Capital Partners

Mehiläinen is the largest healthcare and social care provider in Finland with a fast-growing international presence. As part of its international growth strategy, Mehiläinen has agreed to acquire leading healthcare providers Regina Maria in Romania and MediGroup in Serbia. In conjunction with these major acquisitions, Hellman & Friedman joins CVC in an investment partnership in Mehiläinen. The completion of the acquisitions and new Mehiläinen ownership arrangements is subject to regulatory and customary investor approvals.

Regina Maria is a leading private healthcare company in Romania, offering a wide range of multi-specialty outpatient healthcare services and hospital services. With its 11,000 professionals and 300 units, it serves over 2 million customers annually. Regina Maria’s sister company MediGroup is a leading service provider in the private healthcare market in Serbia with 100 units and over 2,500 employees. The combined revenue of the companies amounted to circa 550 million euros in 2024. The seller in the transaction is the private equity firm MidEuropa.

Regina Maria and MediGroup are highly trusted private healthcare brands with a strong commitment to medical excellence and development of healthcare services. The service offerings and business approach of the companies are closely aligned with those of Mehiläinen, providing a strong basis for future partnership. Regina Maria holds the Joint Commission International (JCI) accreditation, which reflects their hospitals’ high-quality work by proving compliance with international standards for patient safety and care quality. Over the past 15 years, Regina Maria’s entrepreneurial management team has grown the company’s revenue more than tenfold, with most of this growth occurring organically. After the acquisition, Regina Maria’s CEO Fady Chreih and his management team will continue in their current roles.

Alongside these exciting acquisitions Mehiläinen is also pleased to announce that Hellman & Friedman (“H&F”) will become a second major investor in Mehiläinen alongside CVC Funds, which first invested in Mehiläinen in 2018. H&F is a global private equity firm which has been investing in Europe for 25 years and has extensive experience in the healthcare sector.

New investors and funding will accelerate the execution of Mehiläinen’s growth strategy, which focuses on expanding both in Finland and in international markets through a combination of greenfield and service expansion, continuous enhancement of customer experience, and strategic acquisitions, all while keeping the highest standards of patient care and medical quality. The new investment will also support the ongoing international expansion of Mehiläinen’s fast growing Software as a Service business, BeeHealthy, which is already present in over 10 different countries.

Janne-Olli Järvenpää, long-time CEO of Mehiläinen and board member, is pleased with the acquisitions and the owners’ commitment to steady growth: “Regina Maria is one of the fastest-growing and highest-quality healthcare service providers in Europe, led by some of the best professionals in the field. We have closely followed the company’s development for years, and we are truly delighted with the opportunity to partner up with Regina Maria’s management following this acquisition. Regina Maria’s sister company MediGroup is also a leading player in its market with excellent quality. I am also delighted to welcome Hellman & Friedman, who brings significant global healthcare sector expertise, alongside CVC. Mehiläinen’s revenue has grown more than fivefold over the last ten years. Private equity owners with a long-term value creation mindset play a key role in supporting Mehiläinen’s leadership in international expansion and service development.”

“We are honored that the largest healthcare provider in Finland, with over a century of medical experience, recognizes the potential of the medical market in Romania and Serbia. This investment reflects Mehiläinen Group’s confidence in the economic development of the region and marks an extremely significant chapter in our network’s history. We are excited to step into this new stage, where we aim, together, to transform the European landscape of private healthcare, relying on strong management teams and an integrated vision.  Together, we are moving towards a future of increasingly advanced, digitalized, and accessible healthcare, where patient safety and the quality of medical care remain paramount”, said Fady Chreih, CEO of Regina Maria and Chair of the Board of MediGroup.

“Janne-Olli and the rest of the management team have done a tremendous job in transforming Mehiläinen over the past 10 years, all while maintaining their unique entrepreneurial spirit and customer focused culture that is essential to the company’s success”, said Søren Vestergaard-Poulsen, a Managing Partner at CVC. “Mehiläinen is in the forefront of healthcare services trends when it comes to delivery of digitally-enabled multi-specialty outpatient care, with a strong commitment to quality and continuum of care. We look forward to working with the Mehiläinen and Regina Maria management teams to drive Mehiläinen’s next phase of growth, and welcome H&F as our partner on this exciting journey”, added Lave Beck-Friis, Senior Managing Director at CVC.

“Mehiläinen has a long history of excellence in healthcare provision and the business has been going from strength to strength”, said Hunter Philbrick and Stefan Goetz, Partners at Hellman & Friedman. “Its integrated model is at the forefront of healthcare, delivering superior patient outcomes. We look forward to supporting Janne-Olli and the Mehiläinen team on their continued growth and expansion across Europe.”

Other significant direct owners of Mehiläinen beyond CVC and H&F include the company’s management and key personnel, as well as large Finnish pension funds including e.g., Ilmarinen, Varma, and the State Pension Fund. Additionally, there are private investors and smaller institutional investors among the owners.

Categories: News

Tags:

Baird Capital Exits Investment in Collage

Baird Capital

Baird Capital’s Global Private Equity team has announced the sale of its investment in Collage Rehabilitation Partners (Collage).

Baird Capital built Collage through the combination of two well-respected organizations, ReMed and Learning Services Corp., to create a national provider of post-acute rehabilitation services.

Baird Capital’s investment promoted the expansion of Collage’s capabilities and operations from a regional provider focused on supported-living to a national provider with a comprehensive service offering. Over the past seven years, Collage improved its revenue mix toward higher margin active rehabilitation services, enhanced its leadership team and completed five add-on acquisitions to meaningfully expand its geographic presence and service capabilities.

“It has been a privilege to work with Shannon and her talented team at Collage,” said Dennis Hall, Partner at Baird Capital. “They have achieved great success over the past several years. We are excited to watch them continue to develop and support rehabilitation services for many years to come.”

Baird Capital invested in Collage, formerly known as ReMed, in February of 2018.

Categories: News

Tags:

Topcon to Accelerate Growth through Management Buyout with KKR and JIC Capital

KKR

Powerful combination of KKR and JICC creates stable foundations for Topcon to pursue long-term growth

TOKYO–(BUSINESS WIRE)– Topcon Corporation (“Topcon” or the “Company”; TSE stock code 7732) today announced that it is launching a management buyout (“MBO”) led by Topcon President and CEO Takashi Eto. The MBO will receive investment from funds managed by KKR, a leading global investment firm, and JIC Capital (“JICC”), a wholly owned subsidiary of Japan Investment Corporation (“JIC”). In connection with the MBO, TK Co., Ltd. (the “Offeror”), an entity owned by investment funds managed by KKR, intends to make a tender offer for the common shares and share acquisition rights, etc. of the Company. Topcon’s Board of Directors has resolved to support this tender offer and recommends that shareholders and share acquisition right holders tender their securities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327998023/en/

The tender offer price will be JPY 3,300 per share, determined after negotiations between KKR and Topcon.

The proposed tender offer price represents1:

  • A 99.5% premium over the simple average closing price of Topcon’s stock for the 12 months up to December 9, 2024; and
  • A 105.2% premium over the simple average closing price of Topcon’s stock for the 6 months up to December 9, 2024.

KKR is making this investment predominantly from its Asian Fund IV, and it is planned that KKR will indirectly hold a majority interest in Topcon. Following the completion of the tender offer, JICC intends to indirectly hold voting rights in Topcon through JIC PE Fund No. 1 and JIC PE Co-Investment Fund No. 1, investment limited partnerships managed by JICC. Topcon President and CEO Takashi Eto also intends to participate in the tender offer and plans to make a reinvestment after the completion of the tender offer; the details of his investment are yet to be determined.

Topcon is pursuing its long-term vision leading up to its 100th anniversary in 2032, and the Company has been implementing its “Mid-Term Management Plan 2025” covering the fiscal years 2023–2025. Under this plan, Topcon has pursued sustainable business growth and improved profitability by deepening its orientation towards customers, and as the next step, the Company aims to evolve into “New Topcon 2.0,” a business structure that will further accelerate the competitiveness of the Topcon Group. In particular, to transform its eye care business from a hardware-based business to a solutions business, and to achieve further growth in its positioning business, where the competitive environment is rapidly changing, the Company believes that bold, long-term investments and fundamental transformations beyond conventional business reforms are necessary.

Following an in-depth evaluation of all options, Topcon concluded that a management buyout in strategic partnership with KKR and JICC offers the Company the best path to achieve its long-term objectives and enhance its corporate value to benefit all stakeholders, including shareholders. Topcon’s competitive edge lies in the combination of its advanced hardware design and manufacturing capabilities, rooted in Japanese craftsmanship, and its rapidly growing solutions business, particularly in the United States. Topcon believes that it is essential to develop an agile corporate structure to undertake bold investments and implement long-term initiatives. As a private company, the strategic partnership and patient capital support from KKR and JICC will enable Topcon to stay agile, undertake the bold investments and implement the long-term initiatives needed to accelerate its growth and strengthen its competitiveness. Topcon’s current management team will continue to operate the Company and work with its shareholders to implement management initiatives to efficiently and quickly achieve its long-term goals.

Additionally, Topcon leverages its cutting-edge optical technology to develop and manufacture products for the space and defense industry, which is critical to Japan’s national security. Therefore, JICC’s investment will help the Company to develop these business areas and increase its value in the long term.

For KKR, Japan is a key market for its Asia Pacific and global strategy; it has around $18 billion in assets under management in the country. In the ophthalmology sector related to Topcon’s business, KKR has a long track record, including National Vision, an optical retailer in the US; nexeye, a provider of value-for-money eye care in Europe; and Lenskart, an omni-channel eyewear retailer in India, and in the adjacent construction and civil engineering fields within the industrial sector, GeoStabilization International, a provider of geohazard mitigation solutions and roadway safety services in the US. KKR looks to support Topcon’s growth after the privatization by leveraging its global network, deep operational expertise and investment experience in the ophthalmology, healthcare, and industrial sectors to share best practices and help Topcon expand internationally, including in the US, a priority market.

JICC, as a government-affiliated fund, has built deep public-private networks and operational know-how through extensive investment experience in Japan and overseas. JICC will support Topcon’s transformation into a global solutions company centered on its eye care business, which will contribute to the creation of new industries and strengthen international competitiveness, and JICC will support this due to its policy significance. In particular, JICC’s long-term, neutral funds will be essential to support Topcon’s long-term structural reforms and growth strategies. Also, JICC will complement KKR’s private markets expertise, with this combination of public and private funds providing medium- to long-term risk sharing and strong capital and credit alignment.

Takashi Eto, President and CEO of Topcon, said “Today’s announcement represents a crucial step in realizing “Topcon 2.0” and in achieving our long-term vision and to drive future growth. Strategically partnering with KKR and JICC will enable us to focus on bold, agile investments and management initiatives, including structural reforms, without being constrained by potential short-term uncertainties. I am confident that our close alignment between the management team and our future shareholders for this MBO will enable us to address mid- to long-term challenges together, implement management initiatives more effectively, and accelerate our business expansion.”

Hiro Hirano, Deputy Executive Chairman of KKR Asia Pacific and CEO of KKR Japan, said, “We have long admired Topcon’s strong product offering and are delighted to have the opportunity to invest behind their long-term global ambitions. As like-minded strategic partners, we are also pleased to join forces with JICC, who possess a deeply unique understanding of Japan and Topcon’s critical sectors and equal commitment towards the Company’s success. We look forward to collaborating closely with Mr. Eto and his talented management team and JICC to help Topcon accelerate its growth, including through our global network of industry experts and portfolio companies, and achieve its goal of becoming a leading global solutions company.”

Shogo Ikeuchi, President and CEO of JIC Capital, said, “This transaction and joint investment with KKR marks a significant milestone for JICC. We believe that this strategic partnership between our three companies will certainly enhance the stability of Topcon’s management, while at the same time paving the way for KKR to contribute significantly to Topcon’s business. KKR has unique strengths that other investors and companies cannot achieve, and by making the most of KKR’s outstanding strategic insights and resources, we are confident that Topcon will be able to achieve sustainable, stable growth and strengthen its leadership in the global market. Topcon is an excellent example of Japan’s manufacturing prowess, and JICC aims to be a strong partner for Topcon to continue to grow its business in Japan and achieve its bold corporate strategy to transform from a hardware company to a global solutions business with significant overseas growth.”

The tender offer is expected to commence around the end of July 2025, subject to the satisfaction or waiver of certain conditions precedent, including regulatory approvals in Japan and other jurisdictions. For details regarding the conditions of the commencement of the tender offer, please refer to the full text of the release issued by the Offeror today titled, “Notice Regarding the Planned Commencement of Tender Offer for the Shares of Topcon Corporation (Securities Code: 7732) by TK Co., Ltd. as part of the MBO Implementation and Capital Participation by KKR and JICC.”

Forward-looking Statements

This press release should be read in conjunction with the release issued by the Offeror today titled “Notice Regarding the Planned Commencement of Tender Offer for the Shares of Topcon Corporation (Securities Code: 7732) by TK Co., Ltd. as part of the MBO Implementation and Capital Participation by KKR and JICC”.

The purpose of this press release is to publicly announce the tender offer and it has not been prepared for the purpose of soliciting an offer to sell or purchase in the tender offer. When making an application to tender, please be sure to read the Tender Offer Explanatory Statement for the tender offer and make your own decision as a shareholder or share acquisition right holder. This press release does not constitute, either in whole or in part, a solicitation of an offer to sell or purchase any securities, and the existence of this press release (or any part thereof) or its distribution shall not be construed as a basis for any agreement regarding the tender offer, nor shall it be relied upon in concluding an agreement regarding the tender offer.

The tender offer will be conducted in compliance with the procedures and information disclosure standards set forth in Japanese law, and those procedures and standards are not always the same as the procedures and information disclosure standards in the U.S. In particular, neither Sections 13(e) or 14(d) of the U.S. Securities Exchange Act of 1934 (as amended; the same shall apply hereinafter) or the rules under these sections apply to the tender offer; and therefore the tender offer is not conducted in accordance with those procedures and standards. In addition, because the tender offer is a corporation incorporated outside the U.S., it may be difficult to exercise rights or demands against them that can be asserted based on U.S. securities laws. It also may be impossible to initiate an action against a corporation that is based outside of the U.S. or its officers in a court outside of the U.S. on the grounds of a violation of U.S. securities-related laws. Furthermore, there is no guarantee that a corporation that is based outside of the U.S. or its affiliates may be compelled to submit themselves to the jurisdiction of a U.S. court.

Unless otherwise specified, all procedures relating to the tender offer are to be conducted entirely in Japanese. All or a part of the documentation relating to the tender offer will be prepared in English; however, if there is any discrepancy between the English-language documents and the Japanese-language documents, the Japanese-language documents shall prevail.

This press release includes statements that fall under “forward-looking statements” as defined in Section 27A of the U.S. Securities Act of 1933 (as amended) and Section 21E of the Securities Exchange Act of 1934. Due to known or unknown risks, uncertainties or other factors, actual results may differ materially from the predictions indicated by the statements that are implicitly or explicitly forward-looking statements. Neither the Offeror nor any of its affiliates guarantee that the predictions indicated by the statements that are implicitly or expressly forward-looking statements will materialize. The forward-looking statements in this press release were prepared based on information held by the Offeror as of today, and the Offeror and its affiliates shall not be obliged to amend or revise such statements to reflect future events or circumstances, except as required by laws and regulations.

The Offeror, its and the Company’s respective financial advisors and the tender offer agent (and their respective affiliates) may purchase the common shares and share options of the Company, by means other than the tender offer, or conduct an act aimed at such purchases, for their own account or for their client’s accounts, including in the scope of their ordinary business, to the extent permitted under financial instrument exchange-related laws and regulations, and any other applicable laws and regulations in Japan, in accordance with the requirements of Rule 14e-5(b) of the U.S. Securities Exchange Act of 1934 during the tender offer period. Such purchases may be conducted at the market price through market transactions or at a price determined by negotiations off-market. In the event that information regarding such purchases is disclosed in Japan, such information will also be disclosed on the English website of the person conducting such purchases (or by any other method of public disclosure).

If a shareholder exercises its right to demand the purchase of shares of less than one unit in accordance with the Companies Act, the Company may buy back its own shares during the tender offer period in accordance with the procedures required by laws and regulations.

About Topcon Corporation

Topcon Corporation is a global leader in the manufacturing of technology designed to address the essential challenges society faces in healthcare, agriculture, and infrastructure. Topcon specializes in developing optical, sensing and control solutions powered by leading digital transformation technologies for these industries. For more information about Topcon (Tokyo Stock Exchange: 7732), visit: www.global.topcon.com

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About JIC Capital

JIC Capital aims to supply risk capital to achieve policy objectives of creating new businesses and industries to realize Society 5.0, promoting business portfolio transformation for enhancing the international competitiveness, and establishing next-generation social infrastructure to promote Digital Transformation (“DX”).

1 Based on the closing price of Topcon on December 9, 2024, the day before speculative media reporting about the bidding process that impacted the Company’s share price.

Media Inquiries

For Topcon Corporation
Takaaki Hirayama
+81-3-3558-2568 (Media) and +81-3-3558-2532 (Investors)

For KKR
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

For JIC Capital
Communications Group
press@j-ic.co.jp

Source: KKR

 

Categories: News

Tags:

Nagaraja “Sri” Srivatsan Appointed CEO of Endpoint Clinical to Lead Next Phase of Innovation

Arsenal Capital Partners

Raleigh, NC – Endpoint Clinical (“Endpoint”), a global leader in randomization and trial supply management (“RTSM”) solutions and a portfolio company of Arsenal Capital Partners, today announced the appointment of Nagaraja “Sri” Srivatsan as its Chief Executive Officer, effective immediately.

Srivatsan, who has served as an Advisor to Endpoint since January 2024 and as Interim CEO since January 2025, has already played a pivotal role in strengthening the company’s sales strategy, innovation roadmap, and overall growth trajectory.

“Sri has demonstrated exceptional leadership, strategic vision, and an unwavering commitment to Endpoint Clinical’s mission and stakeholders,” said Ray Hill, Chair of the Board of Directors and Operating Partner of Arsenal Capital Partners. “After a comprehensive evaluation, it became clear that he is the right leader to drive Endpoint’s next phase of expansion and technological advancement. We are confident in his ability to propel the company forward and create lasting impact for patients, clinical sites, sponsors and partners worldwide.”

As CEO, Srivatsan will focus on advancing Endpoint’s technology suite, expanding its market presence, scaling operations and delivering solutions that enhance and accelerate the clinical trial process.

“I am honored to lead Endpoint at this exciting time and deeply grateful for the trust placed in me by the Board and our outstanding team,” said Srivatsan. “Endpoint is at a pivotal moment in its journey, and I look forward to accelerating our mission of transforming clinical trial management with reliable, innovative, high-quality, and efficient RTSM solutions. Together, we will continue to push the boundaries of what’s possible in clinical research, delivering unmatched service and technology to our partners.”

Before serving as interim CEO, Srivatsan was Senior Vice President and Chief Digital Officer of Research & Development Solutions at IQVIA. He previously held executive roles as Chief Growth Officer at EXL and Venture Partner, Emerging Business Accelerator at Cognizant. With over 30 years of experience driving innovation in clinical trials across CROs, biopharma, and patient-focused solutions, Srivatsan is well-equipped to lead Endpoint Clinical toward its vision of becoming a market leader in the eClinical space.

About Endpoint Clinical:

Endpoint Clinical is a trusted clinical trial technology and service partner that delivers reliable RTSM solutions. Endpoint seamlessly integrates into clinical trial processes by providing anticipatory and adaptive solutions that proactively mitigate risks. With decades of experience in the field, Endpoint deeply understands the challenges manufacturers face in clinical trials. The company’s tech-forward approach, commitment to innovation, and strategic investments enable it to proactively develop fast and effective solutions, allowing manufacturers to focus on seamless clinical trials. Read more about Endpoint’s solutions at https://www.endpointclinical.com/solutions/.

Categories: People

Tags: